Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprubart vs Tacrolimus in De Novo Kidney Transplantation
NCT07835581Phase 3Not yet recruiting
- Sponsor
- Eledon Pharmaceuticals, Inc.
- Start
- Oct 2026
- Primary completion
- Mar 2029
01
Overview
Phase 3, randomised, open-label trial of tegoprubart in kidney transplant rejection (2 arms), sponsored by Eledon Pharmaceuticals, Inc. Primary endpoint: Efficacy failure rate at 12 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tegoprubart
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT07835581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835581.